MedTrace Logo

Spirulina Oral Supplement for Enhancing Host Resilience to Virus Infection

NCT05447078 · Status: COMPLETED · Phase: PHASE3 · Type: INTERVENTIONAL · Enrollment: 492

Last updated 2025-12-26

No results posted yet for this study

Summary

This randomized, double blind, placebo controlled study aims to establish the impact of the oral supplement, Immulina TM, on enhancing host resilience to the effects of viral influenza infection in humans.

Conditions

  • Healthy Volunteers

Interventions

DRUG

Immulina TM

Immulina TM is a highly standardized extract derived from various preparations of Spirulina, a cyanobacterium, marketed as a dietary supplement and has been utilized in several clinical studies describing its immunopotentiating properties.

DIETARY_SUPPLEMENT

Placebo

Placebo is inert powder in cellulose capsule that appears identical to Immulina TM capsules.

Sponsors & Collaborators

  • National Center for Complementary and Integrative Health (NCCIH)

    collaborator NIH

  • University of Mississippi Medical Center

    lead OTHER

Principal Investigators

  • Gailen D Marshall Jr., MD, PhD · University of Mississippi Medical Center

Study Design

Allocation
RANDOMIZED
Purpose
SUPPORTIVE_CARE
Masking
QUADRUPLE
Model
PARALLEL

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
Yes

Timeline & Regulatory

Start
2022-07-01
Primary Completion
2025-12-08
Completion
2025-12-08
FDA Drug
Yes

Countries

  • United States

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT05447078 on ClinicalTrials.gov